Traws Pharma (NASDAQ:TRAW) Raised to “Strong-Buy” at LADENBURG THALM/SH SH

Traws Pharma (NASDAQ:TRAW) was upgraded by investment analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a note issued to investors on Friday,Zacks.com reports.

Several other research analysts also recently issued reports on TRAW. Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a report on Monday, December 22nd. HC Wainwright started coverage on Traws Pharma in a research note on Wednesday, December 3rd. They set a “buy” rating and a $8.00 price target on the stock. Zacks Research raised Traws Pharma to a “hold” rating in a report on Thursday, December 4th. Finally, Wall Street Zen lowered Traws Pharma from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Traws Pharma Stock Up 0.5%

Shares of NASDAQ TRAW opened at $2.11 on Friday. Traws Pharma has a 12 month low of $0.97 and a 12 month high of $8.61. The company has a market cap of $16.86 million, a P/E ratio of 0.02 and a beta of 1.66. The business’s 50 day moving average is $1.91 and its two-hundred day moving average is $1.94.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Institutional Investors Weigh In On Traws Pharma

A hedge fund recently raised its stake in Traws Pharma stock. Two Sigma Investments LP increased its stake in shares of Traws Pharma, Inc. (NASDAQ:TRAW) by 37.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,018 shares of the company’s stock after buying an additional 5,955 shares during the quarter. Two Sigma Investments LP owned 0.31% of Traws Pharma worth $41,000 at the end of the most recent reporting period. Institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.